Table 2.
Outcome evaluation at baseline and 3 months for program participants versus those in the control group with endometriosis.
| Health outcome | Program participants (n=92), n (%) | Control group (n=149), n (%) | T0a | T0+3 mo | |||||||
|
|
|
|
Program participants, mean (SD) | Control group, mean (SD) | Participants vs control group | Program participants, mean (SD) | Control group, mean (SD) | Participants vs control group | |||
|
|
|
|
|
|
P value | Cohen d |
|
|
P value | Cohen d | |
| Global symptom burden | 90 (97.8) | 147 (98.7) | 5.3 (1.6) | 5.0 (1.6) | .17 | 0.1b | 4.6 (1.6) | 4.7 (1.8) | .75 | –0.0b | |
| Overall pain | 90 (97.8) | 147 (98.7) | 6.2 (2.5) | 6.0 (2.4) | .68 | 0.1b | 5.5 (2.6) | 5.3 (2.6) | .66 | 0.1b | |
| Anxiety | 90 (97.8) | 147 (98.7) | 6.5 (2.2) | 5.9 (2.7) | .12 | 0.2c | 5.5 (2.9) | 6.1 (2.7) | .12 | –0.2c | |
| Depression | 89 (96.7) | 147 (98.7) | 4.0 (3.0) | 4.2 (3.2) | .87 | –0.0b | 3.3 (3.1) | 4.2 (3.3) | .05 | –0.3c | |
| Dysmenorrhea | 35 (38) | 74 (49.7) | 7.3 (1.8) | 6.5 (2.3) | .12 | 0.3c | 5.6 (2.6) | 5.8 (2.6) | .54 | –0.1b | |
| Dyspareunia | 43 (46.7) | 84 (56.4) | 3.9 (2.4) | 4.1 (2.8) | .90 | –0.0b | 3.1 (2.5) | 3.5 (2.7) | .47 | –0.2c | |
| Dyschezia | 90 (97.8) | 147 (98.7) | 3.7 (3.2) | 4.2 (2.8) | .19 | –0.2c | 3.3 (2.7) | 3.6 (2.9) | .60 | –0.1b | |
| Dysuria | 90 (97.8) | 147 (98.7) | 2.2 (2.9) | 1.8 (2.5) | .36 | 0.2c | 1.6 (2.0) | 1.6 (2.4) | .35 | 0.0b | |
| Chronic pelvic pain | 90 (97.8) | 147 (98.7) | 5.2 (2.8) | 4.8 (2.7) | .22 | 0.2b | 4.8 (2.8) | 4.5 (2.7) | .48 | 0.1b | |
| Gastrointestinal disorders | 90 (97.8) | 147 (98.7) | 5.9 (2.7) | 5.3 (2.7) | .10 | 0.2c | 5.7 (2.3) | 5.1 (2.8) | .13 | 0.2c | |
| Chronic fatigue | 90 (97.8) | 147 (98.7) | 7.5 (2.1) | 7.0 (2.2) | .09 | 0.2c | 6.8 (2.3) | 6.8 (2.3) | .77 | –0.0b | |
| Neuropathic pain | 90 (97.8) | 147 (98.7) | 5.4 (3.1) | 4.6 (3.2) | .09 | 0.2c | 4.3 (2.9) | 4.5 (3.0) | .47 | –0.1b | |
| Endo belly | 90 (97.8) | 147 (98.7) | 6.2 (2.5) | 5.7 (2.7) | .09 | 0.2c | 5.4 (2.7) | 5.3 (2.7) | .92 | 0.0b | |
| QOLd: EHP-5e core part | 39 (42.4) | 65 (43.6) | 53.8 (20.4) | 45.2 (20.3) | .04 | 0.0b | 47.9 (19.4) | 46.2 (21.5) | .88 | 0.0b | |
| QOL: EHP-5, modular part | 39 (42.4) | 64 (43) | 34.9 (13.0) | 28.7 (18.4) | .05 | 0.4c | 26.7 (15.4) | 26.4 (18.8) | .59 | 0.0b | |
| QOL: EQ-5D score | 33 (35.9) | 80 (53.7) | 0.8 (0.1) | 0.8 (0.2) | .06 | –0.2c | 0.9 (0.1) | 0.8 (0.2) | .44 | 0.0b | |
aT0: time point 0.
bNo effect size.
cSmall effect size.
dQOL: quality of life.
eEHP-5: Endometriosis Health Profile-5.